CTLA4 and cancer: As a proof of concept of this strategy, we generated an Adenovirus vector encoding a murine anti-CTLA-4 monoclonal antibody (Ad-9D9), and tested its adjuvant effect on adaptive immune responses when co-administered in a mixture with Adenoviral-based vaccines encoding for viral or cancer antigens.